UPS
MCID: UND005
MIFTS: 66

Undifferentiated Pleomorphic Sarcoma (UPS)

Categories: Bone diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Undifferentiated Pleomorphic Sarcoma

MalaCards integrated aliases for Undifferentiated Pleomorphic Sarcoma:

Name: Undifferentiated Pleomorphic Sarcoma 53 59
Malignant Fibrous Histiocytoma 53 73
Ups 53 59
Malignant Fibrohistiocytic Tumors 53

Characteristics:

Orphanet epidemiological data:

59
undifferentiated pleomorphic sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (United States); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: any age;

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

Orphanet 59 ORPHA2023
MESH via Orphanet 45 D051677
UMLS via Orphanet 74 C0334463
ICD10 via Orphanet 34 C49.9
UMLS 73 C0334463

Summaries for Undifferentiated Pleomorphic Sarcoma

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 2023Disease definitionUndifferentiated pleomorphic sarcoma (UPS) is an aggressive sarcoma of soft tissues or bone that can arise from any part of the body, clinically presenting as swelling, mass, pain, pathological fracture and occasional systemic features and is characterized by high local recurrence and significant metastasis.EpidemiologyUPS ranks the 4th most common soft tissue sarcoma with a slight male preponderance. The incidence has been evaluated to be close to 0.8-1 new case per 100000 per year in one European series.Clinical descriptionThe tumor arises most commonly during the sixth and seventh decades of life. The most common sites of involvement include lower extremities (mainly thigh) followed by upper arms, retroperitoneum, viscera, head and neck (in childhood). Primary osseous UPS most commonly occurs in distal femur, proximal tibia, proximal femur and humerus. Patients may present pain, swelling / mass and pathological fractures. In the skin, UPS presents as a relatively painless, rapidly enlarging nodule. Anorexia, malaise, fever and weight loss are present in retroperitoneal and inflammatory forms of UPS. Most UPS recur locally; distant metastases are common (the most frequent is lung). Regional metastases are rare.EtiologyUPS is thought to be derived from a primitive mesenchymal cell capable of differentiating into histiocytes, fibroblasts, myofibroblasts and osteoclasts. The etiology of the tumor remains unknown. Prior radiation therapy is a likely risk factor in some cases.Diagnostic methodsAny tumor mass over 5 cm is suspected to be a sarcoma. Magnetic resonance imaging (MRI) is the imaging method of choice for limbs and shows a high signal on T2 weighted images. Histology of biopsy specimen prior to any treatment is crucial to reach diagnosis and shows pleomorphic spindle cell population with large atypical cells frequently exhibiting numerous irregular mitotic figures, associated regions of hemorrhage and necrosis, associated lymphohistiocytic infiltrate and invasion of dermis. Immunohistochemical staining is negative for S-100, HMB-45, CD34 and cytokeratin which assists in ruling out other soft tissue tumors. Most cases previously diagnosed as malignant fibrous histiocytoma have been reclassified into other histological types of sarcoma.Differential diagnosisWhen occurring in skin, UPS is difficult to differentiate from atypical fibroxanthoma or dermatofibrosarcoma protuberans (see this term). Histological differential diagnoses include leiomyosarcoma, rhabdomyosarcoma, lymphoma, and melanoma (see these terms).Management and treatmentUPS should be referred to an expert/ reference center for primary biopsy, expert pathology review, and multidisciplinary treatment. Immediate surgery of a mass without knowledge of its histological nature is strongly discouraged because it is associated with an increased risk of death due to inappropriate resection and increased risk of relapse. UPS is best treated by wide surgical excision. Sometimes amputation may be necessary to remove the whole lesion. Adjuvant radiotherapy is given for high-grade, large (>5 cm), deep-seated tumors, in limb sparing surgeries and when negative margins are not obtained. For non-operable sarcomas, primary radiation therapy could be an option, but usually doxorubicin containing regimens are preferred options in first-line setting for locally irresectable and/or metastatic lesions. Chemotherapy (CHT) with ifosfamide, trabectedin, dacarbazine, pazopanib have demonstrated efficacy in UPS and are registered and available in most European Union countries.PrognosisA 5-year overall survival rate of 48% has been reported for patients with head and neck tumors versus 77% for patients with tumors arising on the trunk and extremities. The childhood variant appears have better prognosis.Visit the Orphanet disease page for more resources.

MalaCards based summary : Undifferentiated Pleomorphic Sarcoma, also known as malignant fibrous histiocytoma, is related to oligodendroglioma and enchondroma. An important gene associated with Undifferentiated Pleomorphic Sarcoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are HIV Life Cycle and TGF-Beta Pathway. The drugs Beleodaq and Busulfex have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and skin, and related phenotypes are fever and fatigue

Wikipedia : 76 Undifferentiated pleomorphic sarcoma (UPS), previously malignant fibrous histiocytoma (abbreviated MFH),... more...

Related Diseases for Undifferentiated Pleomorphic Sarcoma

Diseases related to Undifferentiated Pleomorphic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 3893)
# Related Disease Score Top Affiliating Genes
1 oligodendroglioma 31.3 IDH1 IDH2 PDGFRA
2 enchondroma 30.5 IDH1 IDH2
3 desmoid tumor 30.3 KIT PDGFRA
4 carcinosarcoma 30.2 KIT KRAS PIK3CA
5 differentiated thyroid carcinoma 30.2 KRAS MET NTRK1
6 gastrointestinal stromal tumor 30.0 KIT KRAS PDGFRA
7 thyroid cancer 29.9 KIT KRAS MET NTRK1 PIK3CA
8 lung cancer susceptibility 3 29.7 IDH1 KRAS MET PIK3CA STAT3
9 glioma 29.7 IDH1 IDH2 MET PDGFRA PIK3CA
10 myeloma, multiple 29.6 IDH1 IDH2 KIT KRAS STAT3
11 leukemia, acute myeloid 29.6 IDH1 IDH2 KIT KRAS STAT3
12 intrahepatic cholangiocarcinoma 29.6 IDH1 IDH2 KRAS
13 medulloblastoma 29.5 IDH1 NTRK1 PDGFRA PIK3CA STAT3
14 glioblastoma 29.5 IDH1 IDH2 MET PDGFRA PIK3CA
15 glioma susceptibility 1 29.5 IDH1 IDH2
16 myelodysplastic syndrome 29.5 IDH1 IDH2 KIT KRAS
17 hepatocellular carcinoma 29.5 IDH1 IDH2 KRAS MET MIR152 PIK3CA
18 pulmonary vein stenosis 29.4 KIT PDGFRA
19 pancreas adenocarcinoma 29.4 KRAS MET PIK3CA STAT3
20 spindle cell hemangioma 29.4 IDH1 IDH2
21 squamous cell carcinoma, head and neck 29.3 IDH2 MET PIK3CA STAT3
22 essential thrombocythemia 29.3 IDH1 IDH2 STAT3
23 neurilemmoma 29.2 EZR KIT PDGFRA
24 adenoid cystic carcinoma 29.2 IDH1 KIT KRAS PIK3CA
25 polycythemia vera 29.1 KIT PDGFRA STAT3
26 glioblastoma multiforme 29.1 IDH1 MET PDGFRA PIK3CA STAT3
27 cytogenetically normal acute myeloid leukemia 29.1 IDH1 IDH2
28 adenosquamous carcinoma 29.0 KIT KRAS PIK3CA
29 intestinal disease 28.9 KRAS PIK3CA STAT3
30 gastric adenocarcinoma 28.9 KIT KRAS MET PIK3CA STAT3
31 spinal chordoma 28.9 MET PDGFRA PIK3CA
32 gastrointestinal system disease 28.9 KIT KRAS STAT3
33 intraductal papilloma 28.8 IDH1 IDH2
34 gastric leiomyosarcoma 28.8 KIT PDGFRA
35 myeloproliferative neoplasm 28.8 KIT PDGFRA STAT3
36 brain cancer 28.7 IDH1 IDH2 PDGFRA PIK3CA STAT3
37 hypereosinophilic syndrome, idiopathic 28.7 KIT PDGFRA
38 cholangiocarcinoma 28.7 IDH1 IDH2 KRAS MET MIR152 PIK3CA
39 respiratory system cancer 28.5 KRAS MET PIK3CA STAT3
40 diaphyseal medullary stenosis with malignant fibrous histiocytoma 13.0
41 malignant fibrous histiocytoma of bone 12.6
42 ichthyosis tapered fingers midline groove up 12.1
43 kabuki syndrome 1 12.0
44 malignant fibroxanthoma 11.7
45 porphyria, acute intermittent 11.6
46 malignant skin fibrous histiocytoma 11.5
47 mastocytosis, cutaneous 11.4
48 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 11.4
49 histiocytoma, angiomatoid fibrous 11.3
50 urachal cancer 11.3

Graphical network of the top 20 diseases related to Undifferentiated Pleomorphic Sarcoma:



Diseases related to Undifferentiated Pleomorphic Sarcoma

Symptoms & Phenotypes for Undifferentiated Pleomorphic Sarcoma

Human phenotypes related to Undifferentiated Pleomorphic Sarcoma:

59 32 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
2 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
3 weight loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0001824
4 anorexia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002039
5 abnormality of the musculature 59 32 frequent (33%) Frequent (79-30%) HP:0003011
6 abnormality of the upper limb 59 32 occasional (7.5%) Occasional (29-5%) HP:0002817
7 abnormality of the lower limb 59 32 hallmark (90%) Very frequent (99-80%) HP:0002814
8 abnormality of the peritoneum 59 32 hallmark (90%) Very frequent (99-80%) HP:0002585
9 soft tissue sarcoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0030448
10 abnormal test result 59 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.17 KIT MET
2 Decreased substrate adherent cell growth GR00193-A-2 9.17 KIT
3 Decreased substrate adherent cell growth GR00193-A-3 9.17 MET
4 Decreased substrate adherent cell growth GR00193-A-4 9.17 KIT MET NTRK1

MGI Mouse Phenotypes related to Undifferentiated Pleomorphic Sarcoma:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.33 CD74 EZR IDH1 KIT KRAS LMNA
2 immune system MP:0005387 10.26 CD74 EZR IDH1 KIT KRAS LMNA
3 mortality/aging MP:0010768 10.26 CD74 EZR IDH1 KIT KRAS LMNA
4 hematopoietic system MP:0005397 10.19 CD74 EZR IDH1 KIT KRAS LMNA
5 cardiovascular system MP:0005385 10.18 IDH2 KIT KRAS LMNA MET PDGFRA
6 integument MP:0010771 10.11 KIT KRAS LMNA MLANA NTRK1 PDGFRA
7 digestive/alimentary MP:0005381 10.1 EZR KIT KRAS LMNA MET PDGFRA
8 muscle MP:0005369 10.06 KIT KRAS LMNA MET NTRK1 PDGFRA
9 craniofacial MP:0005382 10.04 KIT KRAS LMNA MET PDGFRA STAT3
10 neoplasm MP:0002006 9.98 IDH2 KIT KRAS MET PDGFRA PIK3CA
11 limbs/digits/tail MP:0005371 9.97 KIT KRAS LMNA MET NTRK1 PDGFRA
12 no phenotypic analysis MP:0003012 9.95 KIT KRAS MET MLANA NTRK1 PDGFRA
13 normal MP:0002873 9.91 KIT KRAS LMNA MET NTRK1 PDGFRA
14 pigmentation MP:0001186 9.8 KIT KRAS LMNA MLANA NTRK1 PDGFRA
15 renal/urinary system MP:0005367 9.73 KIT KRAS LMNA MET PDGFRA STAT3
16 respiratory system MP:0005388 9.7 IDH1 KIT KRAS LMNA MET PDGFRA
17 skeleton MP:0005390 9.56 CD74 IDH1 KIT KRAS LMNA PDGFRA
18 vision/eye MP:0005391 9.17 KIT KRAS LMNA MET NTRK1 PIK3CA

Drugs & Therapeutics for Undifferentiated Pleomorphic Sarcoma

FDA approved drugs:

(show all 34)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
2
Busulfex 18 49 BUSULFAN Orphan Medical February 1999
3
Eloxatin 18 49 OXALIPLATIN Sanofi-aventis August 2002
4
Emend 18 49 APREPITANT FOSAPREPITANT DIMEGLUMINE Merck March 2003
5
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
6
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
7
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
8
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
9
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
10
Iressa 18 49 GEFITINIB AstraZeneca May 2003
11
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
12
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
13
Premarin 18 ESTROGENS CONJUGATED Wyeth July of 2003
14
Synercid I.V. 18 DALFOPRISTIN; QUINUPRISTIN QUINUPRISTIN; DALFOPRISTIN Rhone Poulenc Rorer September 1999
15
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
16
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
17
Vandetanib 18 49 vandetanib AstraZeneca April 2011
18
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
19
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zuplenz 18 ONDANSETRON Strativa Pharmaceuticals July 2010
21
Adcirca 18 TADALAFIL Eli Lilly May 2009
22
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
23
Alvesco 18 CICLESONIDE Nycomed January 2008
24
Cayston 18 AZTREONAM Gilead February 2010
25
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
26
Dymista 18 AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE Meda Pharmaceuticals Inc May 2012
27
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
28
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008
29
Singulair 18 MONTELUKAST SODIUM Merck February 1998
30
Teflaro 18 CEFTAROLINE FOSAMIL Cerexa Nov-10
31
Tequin 18 Bristol-Myers Squibb December, 1999
32
Tygacil 18 TIGECYCLINE Wyeth 2005
33
Zemaira 18 Aventis Behring July 2003
34
Zyflo 18 ZILEUTON Abbott Laboratories January 1997

Drugs for Undifferentiated Pleomorphic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
9
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Lenograstim Approved, Investigational Phase 3 135968-09-1
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
14
Gemcitabine Approved Phase 3,Phase 1,Phase 2 95058-81-4 60750
15 Olaratumab Approved, Investigational Phase 3,Phase 2 1024603-93-7
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
17
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
21 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
23 Anti-Infective Agents Phase 3,Phase 2,Phase 1
24 Antiviral Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
26 Immunologic Factors Phase 3,Phase 1,Phase 2
27 Etoposide phosphate Phase 3,Phase 2
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 1,Phase 2
33 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
34
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
35
Indinavir Approved Phase 2 150378-17-9 5362440
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
38
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
39
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
40
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
41
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 6436030 5284616
42
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
43
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
44
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
45
Pembrolizumab Approved Phase 1, Phase 2,Phase 2 1374853-91-4
46
Nivolumab Approved Phase 2,Phase 1 946414-94-4
47
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
48
Mesna Approved, Investigational Phase 2,Not Applicable 3375-50-6 598
49
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
50
leucovorin Approved Phase 2 58-05-9 6006 143

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
6 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
10 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
11 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
12 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
13 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
15 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
16 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
17 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
19 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
20 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
21 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
25 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
26 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
27 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
28 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
29 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
30 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
31 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
32 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
33 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
34 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
35 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
36 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
37 Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
38 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
39 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
40 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
41 Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy Recruiting NCT03474094 Phase 2
42 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2 Durvalumab;Tremelimumab
43 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma Recruiting NCT03414229 Phase 2 Epacadostat;Pembrolizumab
44 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
45 Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
46 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
47 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
48 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
49 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
50 APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Not yet recruiting NCT03719430 Phase 2 Doxorubicin;Olaratumab;APX005M

Search NIH Clinical Center for Undifferentiated Pleomorphic Sarcoma

Genetic Tests for Undifferentiated Pleomorphic Sarcoma

Anatomical Context for Undifferentiated Pleomorphic Sarcoma

MalaCards organs/tissues related to Undifferentiated Pleomorphic Sarcoma:

41
Bone, Lung, Skin, Liver, Heart, Kidney, Brain

Publications for Undifferentiated Pleomorphic Sarcoma

Articles related to Undifferentiated Pleomorphic Sarcoma:

(show top 50) (show all 611)
# Title Authors Year
1
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. ( 29308306 )
2018
2
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
3
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
4
Undifferentiated pleomorphic sarcoma. ( 29641724 )
2018
5
Undifferentiated Pleomorphic Sarcoma of Pancreas: A Case Report and Review of the Literature for the Last Updates. ( 29955231 )
2018
6
Extended right hepatectomy with inferior vena cava replacement as an aggressive rescue procedure for threatening venous outflow occlusion in a pretreated undifferentiated pleomorphic sarcoma of the liver. ( 29366308 )
2018
7
Undifferentiated Pleomorphic Sarcoma: Factors Predictive of Adverse Outcomes. ( 29787841 )
2018
8
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
9
Cardiac Undifferentiated Pleomorphic Sarcoma Mimicking Left Atrial Myxoma. ( 29551281 )
2018
10
Recurrent Acute Myocardial Infarction Caused by Intra-cardiac Metastatic Undifferentiated Pleomorphic Sarcoma during Cancer Treatment. ( 29629023 )
2018
11
Undifferentiated pleomorphic sarcoma of the orbital region: a case report. ( 29846420 )
2018
12
Undifferentiated Pleomorphic Sarcoma after Pirfenidone Use: A Case Report. ( 29702057 )
2018
13
Mouse genetic background influences whether <i>Hras<sup>G12V</sup></i> expression plus <i>Cdkn2a</i> knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma. ( 29731980 )
2018
14
Primary undifferentiated pleomorphic sarcoma of the thyroid: A case report and review of the literature. ( 29443775 )
2018
15
Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. ( 30249211 )
2018
16
Intracranial malignant fibrous histiocytoma. ( 29685317 )
2018
17
Splenic malignant fibrous histiocytoma with concurrent hypertension and epistaxis in an Alaskan malamute dog. ( 30103739 )
2018
18
The first ever reported case of malignant fibrous histiocytoma of the scalp. ( 30168269 )
2018
19
Treatment of spinal malignant fibrous histiocytoma, a case report and literature review. ( 30527900 )
2018
20
Prognostic significance of microscopic tumor extension in local recurrence of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. ( 30094896 )
2018
21
Aggressive undifferentiated pleomorphic sarcoma of the stomach involving long-term survival: A case report and literature review. ( 30546898 )
2018
22
The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University. ( 30557163 )
2018
23
Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response. ( 30386736 )
2018
24
Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma. ( 30267407 )
2018
25
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. ( 30281149 )
2018
26
Undifferentiated Pleomorphic Sarcoma Metastatic to the Orbit. ( 30289824 )
2018
27
The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1. ( 30303565 )
2018
28
Undifferentiated pleomorphic sarcoma in a patient with Cowden syndrome after radiotherapy for breast cancer. ( 30047560 )
2018
29
Recurrent Undifferentiated Pleomorphic Sarcoma in the Left Atrium. ( 30062306 )
2018
30
Undifferentiated Pleomorphic Sarcoma of Liver: Case Report and Review of the Literature. ( 30105111 )
2018
31
A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. ( 30134855 )
2018
32
A case of undifferentiated pleomorphic sarcoma of the breast with lung and bone metastases. ( 30165321 )
2018
33
Aggressively progressing primary undifferentiated pleomorphic sarcoma in the eyelid: A case report and review of the literature. ( 28471957 )
2017
34
Cardiac undifferentiated pleomorphic sarcoma incidentally diagnosed during mitral valve replacement. ( 28127801 )
2017
35
Radiation therapy for recurrent cardiac undifferentiated pleomorphic sarcoma after three operations. ( 28434140 )
2017
36
Undifferentiated pleomorphic sarcoma of the neck - A case report. ( 29031178 )
2017
37
PDGFRa amplification in multiple skin lesions of undifferentiated pleomorphic sarcoma: A clue for intimal sarcoma metastases. ( 28105789 )
2017
38
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. ( 29099264 )
2017
39
Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma. ( 28762020 )
2017
40
Radiation-induced undifferentiated pleomorphic sarcoma of the heart: A case report. ( 29305110 )
2017
41
Undifferentiated pleomorphic sarcoma: indolent, tail-like recurrence of a high-grade tumor. ( 28932893 )
2017
42
Undifferentiated Pleomorphic Sarcoma and the Importance of Considering the Oncogenic and Immune-Suppressant Role of the Human T-Cell Lymphotropic Virus Type 1: A Case Report. ( 28596939 )
2017
43
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. ( 27900663 )
2017
44
Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma. ( 28891048 )
2017
45
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. ( 29292724 )
2017
46
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. ( 28552826 )
2017
47
Primary Undifferentiated Pleomorphic Sarcoma of the Penis. ( 29230132 )
2017
48
LN2, CD10, and Ezrin Do Not Distinguish Between Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma or Predict Clinical Outcome. ( 28079637 )
2017
49
A Rare Cause of Dyspnea: Undifferentiated Pleomorphic Sarcoma in the Left Atrium. ( 29118888 )
2017
50
Undifferentiated pleomorphic sarcoma of the skin - a UV-induced occupational skin disease? ( 28220622 )
2017

Variations for Undifferentiated Pleomorphic Sarcoma

Cosmic variations for Undifferentiated Pleomorphic Sarcoma:

9 (show top 50) (show all 232)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44151 TP53 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
2 COSM10660 TP53 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 12
3 COSM6911821 SUFU soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.780G>T p.E260D 10:102597163-102597163 12
4 COSM5564171 PTPRT soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3424C>T p.R1142W 20:42106818-42106818 12
5 COSM6933928 PTPRD soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 12
6 COSM5154 PTEN soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.697C>T p.R233* 10:87957915-87957915 12
7 COSM6920563 PIK3CA soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 12
8 COSM6911819 NOTCH4 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2738C>G p.S913C 6:32210879-32210879 12
9 COSM6916495 MTOR soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4799A>G p.E1600G 1:11144721-11144721 12
10 COSM6986229 MDM2 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.865G>A p.A289T 12:68836696-68836696 12
11 COSM532 KRAS soft tissue,upper arm,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.38G>A p.G13D 12:25245347-25245347 12
12 COSM520 KRAS soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 12
13 COSM6986226 KMT2A soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3446G>C p.G1149A 11:118478078-118478078 12
14 COSM6986222 INPP4A soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1621A>C p.I541L 2:98555592-98555592 12
15 COSM483 HRAS soft tissue,upper arm,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 11:534288-534288 12
16 COSM6928717 GREM1 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.404A>G p.E135G 15:32731094-32731094 12
17 COSM6920564 FLT3 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1700A>G p.K567R 13:28034305-28034305 12
18 COSM6928367 FGFR1 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2149C>T p.H717Y 8:38414189-38414189 12
19 COSM6931170 FAT1 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.9700G>A p.E3234K 4:186611539-186611539 12
20 COSM6931169 FAT1 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.9700G>A p.E3234K 4:186611539-186611539 12
21 COSM6913537 ERBB2 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.584G>A p.C195Y 17:39709822-39709822 12
22 COSM6928364 EIF4E soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.346A>G p.T116A 4:98887132-98887132 12
23 COSM1583677 DDR2 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2125C>T p.R709* 1:162776212-162776212 12
24 COSM6931171 CTCF soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1244G>A p.R415Q 16:67621478-67621478 12
25 COSM4283629 CIC soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.4613C>T p.P1538L 19:42294977-42294977 12
26 COSM6928370 CHEK2 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.959A>G p.K320R 22:28699887-28699887 12
27 COSM6913117 CDK6 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.595C>G p.P199A 7:92671478-92671478 12
28 COSM6928718 CD276 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.353G>A p.G118D 15:73702528-73702528 12
29 COSM6986224 BRAF soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.325T>A p.F109I 7:140834788-140834788 12
30 COSM6916145 BCL6 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.787G>A p.E263K 3:187729618-187729618 12
31 COSM6913121 ATRX soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.6106A>T p.K2036* 23:77593700-77593700 12
32 COSM4749459 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
33 COSM6928368 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2149C>T p.H717Y 8:38414189-38414189 12
34 COSM326729 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.139C>A p.H47N 17:7675077-7675077 12
35 COSM99617 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.358C>T p.R120* 17:7674894-7674894 12
36 COSM99615 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 12
37 COSM6928365 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.2149C>T p.H717Y 8:38414189-38414189 12
38 COSM6986225 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.3446G>C p.G1149A 11:118478078-118478078 12
39 COSM6913538 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.539G>A p.C180Y 17:39709822-39709822 12
40 COSM4749460 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.535C>A p.H179N 17:7675077-7675077 12
41 COSM1140133 soft tissue,retroperitoneum,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 12
42 COSM6986230 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.865G>A p.A289T 12:68836696-68836696 12
43 COSM6986221 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1621A>C p.I541L 2:98555592-98555592 12
44 COSM6933926 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.5686T>C p.S1896P 9:8317927-8317927 12
45 COSM1645335 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.818G>A p.R273H 17:7673802-7673802 12
46 COSM6920562 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.168C>A p.Y56* 3:179198993-179198993 12
47 COSM99618 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.637C>T p.R213* 17:7674894-7674894 12
48 COSM99616 soft tissue,bone,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.241C>T p.R81* 17:7674894-7674894 12
49 COSM6928369 soft tissue,lung,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1088A>G p.K363R 22:28699887-28699887 12
50 COSM6986223 soft tissue,lower extremity,malignant fibrous histiocytoma-pleomorphic sarcoma,NS c.1621A>C p.I541L 2:98555592-98555592 12

Expression for Undifferentiated Pleomorphic Sarcoma

Search GEO for disease gene expression data for Undifferentiated Pleomorphic Sarcoma.

Pathways for Undifferentiated Pleomorphic Sarcoma

Pathways related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 IDH1 KIT KRAS LMNA MET PDGFRA
2
Show member pathways
13.46 KIT KRAS MET NTRK1 PDGFRA PIK3CA
3
Show member pathways
13.4 EZR KIT KRAS MET PDGFRA PIK3CA
4
Show member pathways
13.34 KIT KRAS MET NTRK1 PDGFRA STAT3
5
Show member pathways
13.28 KIT KRAS MET PDGFRA PIK3CA STAT3
6
Show member pathways
12.99 KIT KRAS MET NTRK1 PDGFRA
7
Show member pathways
12.93 KIT KRAS MET NTRK1 PDGFRA STAT3
8
Show member pathways
12.92 EZR KIT MET NTRK1 PDGFRA
9
Show member pathways
12.85 KIT KRAS MET PDGFRA PIK3CA
10
Show member pathways
12.85 KIT KRAS MET NTRK1 PDGFRA PIK3CA
11
Show member pathways
12.8 KRAS MET PDGFRA PIK3CA STAT3
12
Show member pathways
12.76 KRAS NTRK1 PDGFRA PIK3CA STAT3
13
Show member pathways
12.72 KIT KRAS NTRK1 PDGFRA PIK3CA STAT3
14
Show member pathways
12.67 KRAS MET PDGFRA PIK3CA STAT3
15 12.66 KIT KRAS MET NTRK1 PDGFRA
16 12.63 KIT KRAS MET NTRK1 PDGFRA PIK3CA
17
Show member pathways
12.62 KIT KRAS MET PDGFRA PIK3CA
18
Show member pathways
12.6 KRAS MET NTRK1 PIK3CA STAT3
19 12.55 EZR KRAS PDGFRA PIK3CA
20
Show member pathways
12.55 KIT KRAS MET NTRK1 PDGFRA PIK3CA
21
Show member pathways
12.52 KRAS PDGFRA PIK3CA STAT3
22 12.49 CD74 KIT MLANA STAT3
23
Show member pathways
12.42 KRAS MET PDGFRA PIK3CA
24
Show member pathways
12.4 KRAS MET PIK3CA STAT3
25
Show member pathways
12.33 KRAS PDGFRA PIK3CA STAT3
26
Show member pathways
12.31 KIT KRAS PDGFRA PIK3CA
27
Show member pathways
12.28 KRAS MET NTRK1 PDGFRA PIK3CA
28
Show member pathways
12.26 KRAS MET PIK3CA STAT3
29
Show member pathways
12.12 KIT KRAS MET NTRK1 PDGFRA
30 12.11 EZR KRAS MET PIK3CA STAT3
31
Show member pathways
12.1 KIT KRAS MET NTRK1 PDGFRA PIK3CA
32
Show member pathways
12.05 EZR PIK3CA STAT3
33 12.03 KRAS PIK3CA STAT3
34
Show member pathways
12.03 KRAS PDGFRA PIK3CA STAT3
35
Show member pathways
12.02 KRAS PIK3CA STAT3
36
Show member pathways
12.01 KRAS PIK3CA STAT3
37
Show member pathways
12.01 KRAS MET PIK3CA STAT3
38 12 KIT MET NTRK1 PDGFRA
39 11.99 KRAS PIK3CA STAT3
40
Show member pathways
11.98 KRAS LMNA MET NTRK1 PDGFRA PIK3CA
41 11.98 EZR KRAS MET MIR152 PDGFRA PIK3CA
42 11.84 KRAS PIK3CA STAT3
43 11.82 KRAS PIK3CA STAT3
44
Show member pathways
11.79 KRAS PIK3CA STAT3
45 11.79 KRAS LMNA MET NTRK1 PDGFRA PIK3CA
46
Show member pathways
11.73 KIT KRAS PIK3CA
47 11.66 EZR KRAS NTRK1 PDGFRA
48
Show member pathways
11.57 NTRK1 PIK3CA STAT3
49
Show member pathways
11.36 MET PIK3CA STAT3
50 11.26 KRAS NTRK1 PDGFRA PIK3CA STAT3

GO Terms for Undifferentiated Pleomorphic Sarcoma

Cellular components related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.35 CD74 KIT MET NTRK1 PDGFRA
2 receptor complex GO:0043235 8.92 KIT MET NTRK1 PDGFRA

Biological processes related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.97 KIT MET NTRK1 PDGFRA PIK3CA
2 phosphorylation GO:0016310 9.93 KIT MET NTRK1 PDGFRA PIK3CA STAT3
3 positive regulation of gene expression GO:0010628 9.91 EZR KIT KRAS LMNA STAT3
4 cytokine-mediated signaling pathway GO:0019221 9.87 KIT KRAS PIK3CA STAT3
5 negative regulation of apoptotic process GO:0043066 9.85 CD74 KIT MET NTRK1 PDGFRA STAT3
6 MAPK cascade GO:0000165 9.84 KIT KRAS MET PDGFRA
7 peptidyl-tyrosine phosphorylation GO:0018108 9.8 KIT MET NTRK1 PDGFRA
8 positive regulation of protein kinase B signaling GO:0051897 9.78 KIT MET PDGFRA PIK3CA
9 negative regulation of neuron apoptotic process GO:0043524 9.77 KRAS NTRK1 PIK3CA
10 liver development GO:0001889 9.73 KRAS MET PIK3CA
11 negative regulation of signal transduction GO:0009968 9.71 KIT MET NTRK1 PDGFRA
12 phosphatidylinositol phosphorylation GO:0046854 9.62 KIT MET PDGFRA PIK3CA
13 female gonad development GO:0008585 9.61 IDH1 PDGFRA
14 2-oxoglutarate metabolic process GO:0006103 9.59 IDH1 IDH2
15 positive regulation of phospholipase C activity GO:0010863 9.58 KIT PDGFRA
16 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.56 KIT MET NTRK1 PDGFRA
17 NADP metabolic process GO:0006739 9.55 IDH1 IDH2
18 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.55 CD74 KIT MET NTRK1 PDGFRA
19 isocitrate metabolic process GO:0006102 9.52 IDH1 IDH2
20 glyoxylate cycle GO:0006097 9.43 IDH1 IDH2
21 positive regulation of MAPK cascade GO:0043410 9.35 CD74 KIT MET NTRK1 PDGFRA
22 phosphatidylinositol-mediated signaling GO:0048015 8.92 EZR NTRK1 PDGFRA PIK3CA

Molecular functions related to Undifferentiated Pleomorphic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.85 IDH1 IDH2 KIT NTRK1 PDGFRA STAT3
2 kinase activity GO:0016301 9.83 KIT MET NTRK1 PDGFRA PIK3CA
3 nucleotide binding GO:0000166 9.78 KIT KRAS MET PDGFRA
4 transmembrane signaling receptor activity GO:0004888 9.71 KIT MET NTRK1 PDGFRA
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 KIT MET PDGFRA
6 protein tyrosine kinase activity GO:0004713 9.62 KIT MET NTRK1 PDGFRA
7 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH1 IDH2
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 KIT MET PDGFRA PIK3CA
9 isocitrate dehydrogenase activity GO:0004448 9.16 IDH1 IDH2
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 KIT MET NTRK1 PDGFRA

Sources for Undifferentiated Pleomorphic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....